Codexis CDXS 深 沪
等待开盘 10-08 09:30:00 美东时间
1.41
+0.050
+3.68%
华盛通- 最 高1.445
- 今 开1.33
- 成交量 95.82万股
- 最 低 1.33
- 昨 收 1.36
- 总市值 1.54亿
- 52周最高 2.98
- 市盈率 静 --
- 换手率 0.88%
- 52周最低 0.9583
- 委 比 -39.37%
- 总股本 1.10亿
- 历史最高 42.01
- 量 比 1.29
- 振 幅 8.46%
- 历史最低 0.9583
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Codexis Enters Agreement With An Unnamed siRNA Drug Innovator To Explore Stereo-Defined Fragment Synthesis Using Its ECO Synthesis Manufacturing Platform
The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM, a capability of ECO Synthesis. Under the agreement, Codexis will use its ECO Synthesis...
09-28 18:03
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
Codexis, Inc. has entered into an agreement with a leading siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform. This collaboration builds on advancements demonstrated at TIDES USA 2026, where Codexis showcased full-length siRNA synthesis with precise control of phosphorothioate stereochemistry via StereoSelectSM. Under the agreement, Codexis will produce stereo-defined oligonucleotide ...
09-28 10:00
Codexis (CDXS) Has a New Rating from Stephens
Codexis received a Buy rating and a $5.00 price target from Stephens analyst to...
09-22 20:56
Codexis to Participate in Cantor Global Healthcare Conference 2026
Codexis, Inc. announced its participation in the Cantor Global Healthcare Conference 2026, scheduled for September 9-11, 2026, in New York. Management will engage in a fireside chat on September 10, 2026, at 9:45 am ET, with a live webcast available on the Company’s Investor Relations website. A replay will be archived for 90 days. Codexis specializes in enzymatic solutions for efficient and scalable therapeutics manufacturing, utilizing its Code...
08-27 13:00
美股大行评级 | 潜在涨幅455.56%！Cardiol Therapeutics获Canaccord Genuity上调目标价至10美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Cardiol Therapeutics"买入"评级，目标价从8美元升至10美元；B. Riley证券：维持Macrogenics"买入"评级，目标价从9美元升至11美元
08-18 11:39
Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8
Piper Sandler analyst Kashy Harrison maintains Codexis (NASDAQ:CDXS) with a Overweight and lowers the price target from $9 to $8.
08-18 00:05
Codexis Appoints David Butler, PhD, to Strategic Advisory Board
Codexis, Inc. has appointed David Butler, PhD, to its Strategic Advisory Board (SAB), bringing over 20 years of experience in oligonucleotide therapeutics, including siRNA and mRNA-based technologies. Butler, previously CTO at Hongene Biotech and with roles at Wave Life Sciences and Alnylam, will support Codexis' growth in enzymatic manufacturing. Carole Cobb is stepping down from the SAB after significant contributions. Codexis leverages its Cod...
08-03 13:00
Codexis to Report Second Quarter 2026 Financial Results on August 11
Codexis, Inc. will report its 2Q 2026 financial results on August 11, 2026, followed by a conference call and webcast at 4:30 pm ET. The live webcast is available on the Codexis Investor Relations website and will be archived for 90 days. Participants can join the call via 877-705-2976 (domestic) or 201-689-8798 (international). A replay will be available for 48 hours at 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635...
07-28 13:00
Why SAP Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Shares of SAP SE (NYSE:SAP) rose sharply in pre-market trading after the company reported second-quarter financial results. SAP reported quarterly earnings of $1.85 per share, which missed the consensus estimate of $2.01 by 7.96%, according to Benzinga Pro data. Quarterly revenue came in at $11.48 b...
07-24 16:35
Codexis falls 20% after pricing $25M stock offering at $1.50/share
Codexis (CDXS) priced a public offering of 16.67M common shares at $1.50/share, at the bottom of its marketed range. Gross proceeds are expected to be approximately $25M, with net proceeds of about $2...
07-24 13:50
